Compare EEX & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEX | PCRX |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | 821 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 890.6M | 1.0B |
| IPO Year | N/A | 2010 |
| Metric | EEX | PCRX |
|---|---|---|
| Price | $4.98 | $23.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.70 | ★ $30.25 |
| AVG Volume (30 Days) | ★ 714.2K | 517.6K |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $7.49 | $6.78 |
| Revenue Next Year | $6.81 | $8.54 |
| P/E Ratio | ★ $236.96 | $338.29 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $3.32 | $18.80 |
| 52 Week High | $5.45 | $27.64 |
| Indicator | EEX | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.33 | 48.10 |
| Support Level | $4.81 | $22.06 |
| Resistance Level | $5.09 | $24.20 |
| Average True Range (ATR) | 0.03 | 1.04 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 13.65 | 44.31 |
Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States, with operations in the United Kingdom (U.K.), France, and other markets. The company is engaged in three complementary business lines: Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division provides B2B e-commerce and digital merchandising solutions to manufacturers and retailers. Emerald's key revenue is derived from the Connections business, its only reportable segment.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.